Plain-English translation of NCT06405321 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a retrospective study that examines medical records of liver cancer patients across multiple hospitals in Guangxi, China. Researchers want to understand how different early treatment approaches—including chemotherapy, targeted drugs, immunotherapy, and radiation—help patients with advanced liver cancer. By studying what worked best for patients already treated, they hope to identify the best strategies for future patients.
More than half of liver cancer patients are diagnosed at an advanced stage when the cancer is harder to treat. New medications and treatment combinations are giving more patients a chance at curative treatment, but doctors still aren't certain which combinations work best for which patients or when to use them.
You likely qualify if…
You likely don't qualify if…
This study reviews your existing medical records—you do not need to visit the hospital or receive new treatment. Researchers will collect information about your diagnosis, the treatments you received, how you responded, and your follow-up care. The study involves no additional visits, tests, or procedures beyond what you have already had as part of your regular cancer care.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Sponsor
Guangxi Medical University
Enrollment target
~2,000 participants
Started
January 2019
Primary completion
December 2026
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jian-Hong Zhong, Ph.D
Guangxi Medical University Cancer Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.